All In Biotech

Drug Trial Radar · NCT07402915

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

An Open-label, Fixed Sequence Phase I Study to Evaluate the Effect of Itraconazole (a Strong CYP3A Inhibitor) on the Pharmacokinetics of AZ14170132, the TOP1 Inhibitor Payload of the Antibody Drug Conjugate AZD5335, in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jan 26, 2026

Primary completion

Oct 15, 2027

Study completion Oct 15, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.

Conditions

  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal

Interventions

  • AZD5335Drug

    AZD5335 will be administered as IV infusion.

  • ItraconazoleDrug

    Itraconazole capsule will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under curve from time 0 to time 17 days (AUC0-17days)Time frame: Cycle 2 and Cycle 3 (each cycle is of 21 days)
  2. Maximum plasma drug concentration (Cmax)Time frame: Cycle 2 and Cycle 3 (each cycle is of 21 days)

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Batumi, Georgia · Withdrawn

  • Research Site

    Tbilisi, Georgia · Withdrawn

  • Research Site

    Tbilisi, Georgia · Withdrawn

  • Research Site

    Dublin, Ireland · Recruiting

  • Research Site

    Lisbon, Portugal · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Logroño, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.